Summary
A Bayesian framework for group testing under dilution effects has been developed, using latticebased models. This work has particular relevance given the pressing public health need to enhance testing capacity for COVID-19 and future pandemics, and the need for wide-scale and repeated testing for surveillance under constantly varying conditions. The proposed Bayesian approach allows for dilution effects in group testing and for general test response distributions beyond just binary outcomes. It is shown that even under strong dilution effects, an intuitive group testing selection rule that relies on the model order structure, referred to as the Bayesian halving algorithm, has attractive optimal convergence properties. Analogous look-ahead rules that can reduce the number of stages in classification by selecting several pooled tests at a time are proposed and evaluated as well. Group testing is demonstrated to provide great savings over individual testing in the number of tests needed, even for moderately high prevalence levels. However, there is a trade-off with higher number of testing stages, and increased variability. A web-based calculator is introduced to assist in weighing these factors and to guide decisions on when and how to pool under various conditions. High performance distributed computing methods have also been implemented for considering larger pool sizes, when savings from group testing can be even more dramatic.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by grants NSF DRL-1561716, R01 MH65538, NSF CCF-2132049 and UL1TR002548.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This work does not involve data.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
With help from the useful and careful reviewer comments, we have greatly improved the manuscript. It is presented more clearly, and we have included more extensive and numerically accurate simulations. Also, improved underlying numerical algorithms have allowed us to compute performance statistics for larger pool sizes. We have updated the open source codes accordingly.
Data Availability
This work does not involve data.
